Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL).
The Society for Immunotherapy of Cancer (SITC) consensus statement on immunother...
The SITC convened an expert panel,to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations.
Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic l...
Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in the treatment of chronic lymphocytic leukemia (CLL). However, efficacy seems to be inferior compared to diffuse large B‐cell lymphoma or acute lymphoblastic leukemia. Impaired T‐cell fitness of CLL patients may be involved in treatment failure.
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Cost of decentralized CAR T‐cell production in an academic nonprofit setting
Decentralized T‐cell production might be a less costly and more efficient alternative to the current centralized production mode that requires a high acquisition cost.
Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine ...
This report describes a case of relapsed/refractory ETP-ALL that responded to the combination of venetoclax and nelarabine, when administered as fourth line therapy.
The Emerging Role of Convalescent Plasma in the Treatment of COVID-19
A detailed overview of randomized as well non-randomized trials of treatment with convalescent plasma, which have been registered worldwide, is provided in this review.
Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia a...
Findings in this report are in line with important important findings of recent studies on eculizumab providing a control population of AA patients with and without PNH clones
The promise of CAR-T cell therapy
Innovative Medicine Initiative (IMI) is a EU public-private partnership funding health research and innovation. Complex therapies like CAR-T cells pose questions no drug developer can answer on thei own.
Death receptor pathway drives resistance to CAR T-cell therapy
Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T-cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why. Read the full article here